Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4503093 | 0.92 | PTGER4 (0.42) | UCHL1NOTUMPTGER4PTGER2MAPK1 | |
| SCHEMBL3500666 | 0.84 | MPO (0.39) | MPOL3MBTL1KDM1ABRD4 | |
| SCHEMBL6108617 | 0.83 | P2RX1 (0.50) | MEN1KMT2AMPOL3MBTL1UCHL1 | |
| SCHEMBL16593635 | 0.83 | NOTUM (0.41) | MEN1KMT2AMPOL3MBTL1UCHL1 | |
| SCHEMBL7349579 | 0.81 | UCHL1 (0.41) | MEN1KMT2AUCHL1NOTUMPTGER4 | |
| SCHEMBL31139409 | 0.81 | MEN1 (0.46) | MEN1KMT2AL3MBTL1NOTUMMAPK1 | |
| SCHEMBL3502782 | 0.80 | UCHL1 (0.45) | MEN1KMT2AMPOUCHL1NOTUM | |
| SCHEMBL3133623 | 0.80 | L3MBTL1 (0.39) | MEN1KMT2AMPOL3MBTL1UCHL1 | |
| SCHEMBL29183525 | 0.80 | PTGER4 (0.41) | L3MBTL1UCHL1NOTUMPTGER4PTGER2 | |
| SCHEMBL13709195 | 0.79 | ESR2 (0.40) | UCHL1NOTUMPTGER4PTGER2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2096109-A1 | CARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | GPR119, GPR65, HCAR1 | MEN1 3086/4885KMT2A 3440/4885MPO 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.